of Work: The pharmacological and physiological activity of recently developed opioid mimetic substances were determined in vivo using mice in comparion to morphine and using general as well as specific opiate antagonists to assess their mode of action. The antinociception profile paralled that of the in vitro functional pharmacological data using guinea-pig ileum and mouse vas deferens assay systems, and reflected the receptor binding affinity (see previous projects for details on the interaction of peptides with delta- and mu-opioid receptors). A series of novel Dmt-containing pyrazinone opioid mimetic compounds had exceptional activity in vivo, one of which was 60- to 71-fold more potent than morphine in generating analgesia using standard testing procedures after i.c.v. administration, but depending on whether the test measured spinal or supraspinal effects; the former being more potent than the latter. In particular, the compound 3-[4'-Dmt-aminobutyl)-6-(3'-Dmt-aminopropyl0-5-methyl-2(1H)pyrazinone had very high affinity (Ki mu = 0.02 nM), selectivity (delta/mu = 1,520) and agonist activity (GPI, IC50 = 1.7 nM) with weak activity toward the delta receptor in all assay systems. This compound acted to produce spinal antinociception primarily through spinal antinociception using the mu-2 receptor subtype; however, the mu-1 subtype dominates supraspinally. The s.c. injection produced CNS-mediated antinociception, providing evidence the compound passed through memrane barriers in both the gastrointestinal tract and in the microcapillary tight junctions in the brain. However, a tolerance was obtained after a week that was equivalent to morphine that suggests that both substances act through similar mechanisms at mu-opioid receptors. Another class of Dmt-containing pyrazinone compounds, the 3,6-bis-[Dmt-NH-(CH2)n]-2(1H)-pyrazinone compounds not only exhibited central (CNS) mediated analgesia, but also were orally bioavailable opioid mimetics. These symmetric substances displayed high affinity for mu-opioid receptors (Ki = 0.04-0.12 nM) and potent angonism on GPI (IC50 = 1.3-1.9 nM). They produced analgesia in vivo by i.c.v. administration that was 50- to 63-fold more potent than morphine, but only about half as potent when injected s.c. or administered orally, which is still orders of magnitude greater than other endogenous opioid peptides and, importantly, were unmodified by glycosylation, adamantane, triglycerides, halogens, antibody, biotin, bulky organic molecules, esterification of a C-terminal carboxyl group (of which none exist in these compounds) or O-acylation of the phenolic hydroxyal group of Tyr or Dmt, nor was it necessary to absorb them onto polysorbate coated nanoparticles to induced uptake through the BBB.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Intramural Research (Z01)
Project #
1Z01ES100472-02
Application #
6838631
Study Section
(LCBR)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2003
Total Cost
Indirect Cost
Name
U.S. National Inst of Environ Hlth Scis
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Lazarus, Lawrence H; Okada, Yoshio (2012) Engineering endomorphin drugs: state of the art. Expert Opin Ther Pat 22:1-14
Marczak, Ewa D; Jinsmaa, Yunden; Myers, Page H et al. (2009) Orally administered H-Dmt-Tic-Lys-NH-CH2-Ph (MZ-2), a potent mu/delta-opioid receptor antagonist, regulates obese-related factors in mice. Eur J Pharmacol 616:115-21
Balboni, Gianfranco; Trapella, Claudio; Sasaki, Yusuke et al. (2009) Influence of the side chain next to C-terminal benzimidazole in opioid pseudopeptides containing the Dmt-Tic pharmacophore. J Med Chem 52:5556-9
Vergura, Raffaella; Balboni, Gianfranco; Spagnolo, Barbara et al. (2008) Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist. Peptides 29:93-103
Jinsmaa, Yunden; Marczak, Ewa D; Balboni, Gianfranco et al. (2008) Inhibition of the development of morphine tolerance by a potent dual mu-delta-opioid antagonist, H-Dmt-Tic-Lys-NH-CH2-Ph. Pharmacol Biochem Behav 90:651-7
Balboni, Gianfranco; Fiorini, Stella; Baldisserotto, Anna et al. (2008) Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem 51:5109-17
Koda, Yasuko; Del Borgo, Mark; Wessling, Susanne T et al. (2008) Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg Med Chem 16:6286-96
Salvadori, Severo; Fiorini, Stella; Trapella, Claudio et al. (2008) Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem 16:3032-8
Ryu, Eun Kyoung; Wu, Zhanhong; Chen, Kai et al. (2008) Synthesis of a potent and selective (18)F-labeled delta-opioid receptor antagonist derived from the Dmt-Tic pharmacophore for positron emission tomography imaging. J Med Chem 51:1817-23
Balboni, Gianfranco; Onnis, Valentina; Congiu, Cenzo et al. (2007) Further studies on the effect of lysine at the C-terminus of the Dmt-Tic opioid pharmacophore. Bioorg Med Chem 15:3143-51

Showing the most recent 10 out of 38 publications